EV
EVGN.US Evogene
- Market cap
- USD 6.70M
- P/E
- -
- P/B
- 4.71x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is EVGN.US undervalued?
Graham numberThe Graham number of Evogene cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evogene fundamental analysis
No fundamental analysis for Evogene yet.
Evogene stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the dev…
Full company profileEvogene financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evogene annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.54M | 3.38M | 1.75M | 753K | 1.04M | 930K | 1.68M | 2.98M | 5.58M | 3.85M | 1.36M |
| Gross Profit | 901K | 536K | 295K | 419K | 466K | 163K | 766K | 1.49M | 3.20M | -241K | 392K |
| Operating Income | -21.1M | -21.9M | -20.0M | -21.2M | -24.8M | -31.0M | -26.9M | -22.2M | -18.8M | -14.0M | -11.2M |
| EBITDA | -18.8M | -18.7M | -18.8M | -16.0M | -23.2M | -27.9M | -27.0M | -20.5M | -13.4M | -12.2M | -8.22M |
| Net Income | -19.6M | -20.8M | -20.8M | -18.1M | -23.4M | -27.8M | -26.6M | -23.9M | -16.5M | -8.49M | -15.3M |
| EPS | -0.77 | -0.81 | -0.81 | -0.70 | -0.64 | -0.68 | -6.46 | -5.23 | -2.89 | -1.08 | -1.25 |
| Balance Sheet | |||||||||||
| Total Assets | 96.0M | 77.6M | 58.7M | 71.4M | 71.9M | 76.3M | 56.1M | 51.1M | 39.9M | 20.0M | 13.4M |
| Total Liabilities | 8.70M | 8.22M | 8.39M | 11.1M | 15.0M | 12.9M | 21.3M | 22.4M | 25.0M | 8.07M | 7.67M |
| Shareholders' Equity | 87.3M | 69.4M | 50.1M | 50.1M | 46.0M | 53.7M | 27.9M | 12.1M | -1.45M | -82.0K | -3.29M |
| Cash & Short-term Investments | 88.1M | 71.8M | 54.5M | 46.9M | 48.2M | 53.9M | 35.4M | 31.1M | 15.3M | 13.0M | 9.35M |
| Total Debt | - | - | - | 2.97M | 2.44M | 2.67M | 11.9M | 11.5M | 12.9M | 2.20M | 2.10M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.7M | -15.9M | -15.2M | -17.4M | -19.5M | -24.8M | -23.7M | -21.6M | -19.7M | -13.5M | -10.1M |
| Capital Expenditure | 808K | 590K | 374K | 900K | 682K | 724K | 1.17M | 785K | 626K | 135K | 22.6K |
| Free Cash Flow | -12.5M | -16.5M | -15.5M | -18.3M | -20.2M | -25.6M | -24.8M | -22.4M | -20.3M | -13.6M | -10.1M |
| Ratios | |||||||||||
| ROE | -22.4% | -30.0% | -41.5% | -36.1% | -50.8% | -51.8% | -95.4% | -198.1% | - | - | - |
| ROA | -20.4% | -26.9% | -35.4% | -25.4% | -32.5% | -36.4% | -47.5% | -46.7% | -41.4% | -42.3% | -113.7% |
| Net Profit Margin | -299.6% | -616.3% | -1,188.2% | -2,405.3% | -2,247.5% | -2,988.5% | -1,590.3% | -800.8% | -295.6% | -220.2% | -1,121.6% |
| Debt to Equity | - | - | - | 0.06x | 0.05x | 0.05x | 0.43x | 0.95x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evogene dividends
Evogene has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jul 25, 2024.
Who owns Evogene
- Insiders 24.39%
- Institutions 4.93%
- Public & others 70.69%
- Shares outstanding 18.1M
- Free float 12.4M
Top funds holding EVGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| P & S Renditefonds T | 10.0K | 0.11% | 0.00% | Aug 2026 |
Top institutions holding EVGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 107K | 0.68% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 80.1K | 0.51% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 50.5K | 0.32% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 19.4K | 0.12% | +52.54% | Jun 2026 |
| UBS Group AG | 10.8K | 0.07% | +69.87% | Jun 2026 |
| Daytona Street Capital LLC | 9.25K | 0.06% | -3.47% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 2.83K | 0.02% | -68.98% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.29K | 0.01% | -66.63% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 500.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 100.00 | 0.00% | 0.00% | Jun 2026 |
| SHP Wealth Management | 65.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 62.00 | 0.00% | -13.89% | Jun 2026 |
| Royal Bank of Canada | 42.00 | 0.00% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Tradewinds Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Evogene company profile
- Company name
- Evogene
- Ticker
- EVGN.US
- ISIN
- IL0011050551
- Exchange
- USA Stocks
- Listed since
- Mar 5, 2008
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Fiscal year end
- December
- Address
- 13 Gad Feinstein Street, Rehovot, Israel, 7638517
- Phone
- 972 8 931 1900
- Website
- evogene.com
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Evogene management
6- Mr. Ofer Haviv CPACEO, President, CFO & Director · born 1966
- Mr. Yoash ZoharChief Executive Officer of Casterra Ag Ltd. · born 1967
- Dr. Dan Jacob Gelvan Ph.D.Chief Executive Officer of Ag Plenus Ltd. · born 1964
- Dr. Ilia ZhidkovChief Technology Officer · born 1977
- Ms. Liat Foigel WejgmanVice President of Human Resources
- Dr. Gabi Tarcic Ph.D.Chief Development Officer · born 1980